1061338-75-7

Basic information

• Product Name: (R)-N-(2,2-dimethylpropyl)-3-{(2S,3S)-3-[(2S)-2-amino-3,3-dimethylbutanoylamino]-2-hydroxy-4-phenylbutanoyl}-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
• Synonyms: (R)-N-(2,2-dimethylpropyl)-3-{(2S,3S)-3-[(2S)-2-amino-3,3-dimethylbutanoylamino]-2-hydroxy-4-phenylbutanoyl}-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
• CAS NO: 1061338-75-7
• Molecular Weight: 520.737
• Mol File: 1061338-75-7.mol

Chemical Properties

• CAS DataBase Reference: (R)-N-(2,2-dimethylpropyl)-3-{(2S,3S)-3-[(2S)-2-amino-3,3-dimethylbutanoylamino]-2-hydroxy-4-phenylbutanoyl}-5,5-dimethyl-1,3-thiazolidine-4-carboxamide(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-N-(2,2-dimethylpropyl)-3-{(2S,3S)-3-[(2S)-2-amino-3,3-dimethylbutanoylamino]-2-hydroxy-4-phenylbutanoyl}-5,5-dimethyl-1,3-thiazolidine-4-carboxamide(1061338-75-7)
• EPA Substance Registry System: (R)-N-(2,2-dimethylpropyl)-3-{(2S,3S)-3-[(2S)-2-amino-3,3-dimethylbutanoylamino]-2-hydroxy-4-phenylbutanoyl}-5,5-dimethyl-1,3-thiazolidine-4-carboxamide(1061338-75-7)

Safety Data

• Hazardous Substances Data: 1061338-75-7(Hazardous Substances Data)

Upstream product

• 72778-00-8 (R)-5,5-dimethyl-1,3-thiazolidine-4-carboxylic acid 
• 62023-62-5 allophenylnorstatine 
• 117918-23-7 (R)-3-tert-butoxycarbonyl-5,5-dimethyl-1,3-thiazolidine-4-carboxylic acid 
• 62023-65-8 (2S,3S)-3-tert-butoxycarbonylamino-2-hydroxy-4-phenylbutanoic acid 
• 62965-35-9 N-tert-butyloxycarbonyl-L-tert-leucine 
• 5813-64-9 2.2-dimethylpropylamine 
• 20859-02-3 L-tert-Leucine 
• 1061338-63-3 (R)-N-(2,2-dimethylpropyl)-3-[(2S,3S)-3-amino-2-hydroxy-4-phenylbutanoyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide 
• 1061338-51-9 (R)-N-(2,2-dimethylpropyl)-5,5-dimethyl-1,3-thiazolidine-4-carboxamide 

Downstream Products

• 1300049-14-2 KNI-10751 
• 1061337-79-8 KNI-10680 
• 1061727-56-7 KNI-10635 
• 1300049-24-4 KNI-10754 
• 1301120-29-5 KNI-10842 
• 1300049-16-4 KNI-10750 
• 1300049-26-6 KNI-10814 
• 1300049-18-6 KNI-10776 
• 1300049-09-5 KNI-10748 
• 1300049-21-1 KNI-10755 
• 1300049-11-9 KNI-10747 
• 1300049-23-3 KNI-10817 
• 1301120-28-4 KNI-10775 

Relevant articles and documents

Design and synthesis of several small-size HTLV-I protease inhibitors with different hydrophilicity profiles

The human T cell leukemia/lymphotropic virus type 1 (HTLV-I) is clinically associated with adult T cell leukemia/lymphoma, HTLV-I associated myelopathy/tropical spastic paraparesis, and a number of other chronic inflammatory diseases. To stop the replication of the virus, we developed highly potent tetrapeptidic HTLV-I protease inhibitors. In a recent X-ray crystallography study, several of our inhibitors could not form co-crystal complexes with the protease due to their high hydrophobicity. In the current study, we designed, synthesized and evaluated the HTLV-I protease inhibition potency of compounds with hydrophilic end-capping moieties with the aim of improving pharmaceutic and pharmacokinetic properties.

Maintaining potent HTLV-I protease inhibition without the P3-cap moiety in small tetrapeptidic inhibitors

The human T cell lymphotropic/leukemia virus type 1 (HTLV-I) causes adult T cell lymphoma/leukemia. The virus is also responsible for chronic progressive myelopathy and several inflammatory diseases. To stop the manufacturing of new viral components, in our previous reports, we derived small tetrapeptidic HTLV-I protease inhibitors with an important amide-capping moiety at the P3 residue. In the current study, we removed the P3-cap moiety and, with great difficulty, optimized the P3 residue for HTLV-I protease inhibition potency. We discovered a very potent and small tetrapeptidic HTLV-I protease inhibitor (KNI-10774a, IC50 = 13 nM).

Locking the two ends of tetrapeptidic HTLV-I protease inhibitors inside the enzyme

Adult T-cell leukemia and tropical spastic paraparesis/HTLV-I-associated myelopathy are only some of the more common end results of an infection with a human T-cell leukemia virus type 1 (HTLV-I). Expanding from our previous reports, we synthesized all different permutations of tetrapeptidic HTLV-I protease inhibitors using at least eight P3-cap and five P1′-cap moieties. The inhibitors exhibited over 97% inhibition against HIV-1 protease and a wide range of inhibitory activity against HTLV-I protease.

Truncation and non-natural amino acid substitution studies on HTLV-I protease hexapeptidic inhibitors

The culprit behind adult T-cell leukemia, myelopathy/tropical paraparesis, and a plethora of inflammatory diseases is the human T-cell leukemia virus type 1 (HTLV-I). We recently unveiled a potent hexapeptidic HTLV-I protease inhibitor, KNI-10166, compose